The diagnosis of Amyotrophic Lateral Sclerosis by V. Silani et al.
Introduction
The term Amyotrophic lateral sclerosis (ALS) cov-
ers a spectrum of neurodegenerative syndromes 
characterized by progressive degeneration of motor 
neurons (MNs). Other syndromes related to this 
spectrum of disorders include Progressive bul-
bar palsy (PBP), Progressive muscular atrophy 
(PMA), Primary lateral sclerosis (PLS), Flail arm 
syndrome (Vulpian-Bernhardt syndrome), Flail leg 
syndrome, and ALS with multi-system involvement 
(e.g., ALS-Dementia). These syndromes share a 
common molecular and cellular pathology compris-
ing of MN degeneration and the presence of charac-
teristic ubiquitin-(Ub) and TDP-43-immunoreactive 
(TDP43) intraneuronal inclusions.
Definition and criteria relevant
for diagnosis
ALS can be defined as a neurodegenerative disorder 
characterized by progressive muscular paralysis 
reflecting degeneration of MNs in the primary motor 
cortex, brainstem, and spinal cord. “Amyotrophy” 
refers to the atrophy of muscle fibers, leading 
to weakness of affected muscles and fascicula-
tions. “Lateral sclerosis” refers to hardening of the 
anterior and lateral corticospinal tracts as MNs in 
these areas degenerate and are replaced by gliosis 
(Rowland and Shneider, 2001). In the absence of 
any established biological marker, the diagnosis of 
ALS is based on the presence of characteristic clini-
cal findings in conjunction with investigations to 
exclude “ALS-mimic” syndromes: cervical radicu-
lomyelopathy leads to diagnostic error in 5-10% 
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of cases (Davenport et al., 1994; Traynor et al., 
2000a). Signs suggestive of combined upper (UMN) 
and lower motor neuron (LMN) impairment that 
cannot be explained by any other disease process 
(evident on electrophysiological, imaging, cerebro-
spinal fluid (CSF), or serological studies), together 
with progression compatible with a neurodegenera-
tive process, is invariably suggestive of ALS. Thus, 
neurophysiological results alone (e.g., evidence of 
chronic denervation on electromyography or EMG) 
are not adequate for achieving a diagnosis, and must 
be interpreted in light of the patient’s history and 
clinical findings.
The World Federation of Neurology (WFN) 
Research Group on Motor Neuron Diseases have 
developed the 1994 “El Escorial” diagnostic criteria 
(Brooks et al., 1994) and the revised 2000 “Airlie 
House” criteria (Brooks et al., 2000) to aid in diag-
nosing and classifying patients for research studies 
and drug trials. Based on these criteria patients can 
be classified into “Clinically definite”, “Clinically 
probable”, “Clinically probable - Laboratory sup-
ported” and “Clinically possible” categories. In the 
previous 1994 classification, patients with a pure 
LMN syndrome were classified into the “Clinically 
suspected” category, which was removed from the 
revised criteria. However, it is well recognized that 
a significant number of patients who either have 
a pure LMN syndrome or who early in the course 
of the disease do not have obvious UMN signs, 
will undoubtedly have ALS (or a variant) but will 
not fall into these categories in the revised criteria. 
Therefore, these criteria are probably more useful 
for research purposes and therapeutic trials, rather 
than day-to-day clinical practice and early diag-
nosis. A recent rationalization of the El Escorial 
Criteria with the Awaji consensus simplifies the 
criteria (de Carvalho et al., 2008). In contrast to 
previous criteria the so-called Awaji-Criteria are 
designed for everyday clinical practise. In essence it 
is recommended that electrophysiological evidence 
of chronic neurogenic changes should be taken as 
equivalent to clinical information in the recognition 
of LMN involvement and fasciculation potentials 
should be taken as equivalent of two signs of active 
denervation.
Relevant epidemiology for diagnosis
Epidemiology may offer useful informations to the 
clinicians, orienting early diagnosis: the incidence 
of sporadic ALS in the 1990’s was reported to be 
between 1.5 and 2.7 per 100,000 population/year 
(average 1.89 per 100,000/year) in Europe and 
North America (Worms, 2001). The point preva-
lence ranges from 2.7 to 7.4 per 100,000 (average 
5.2 per 100,000) in Western countries (Worms, 
2001). The lifetime risk of SALS by the age of 70 
has been estimated at 1 in 1,000 (Chancellor et al., 
1993; Traynor et al., 1999) but a more accurate esti-
mate is more likely to be 1 in 400 (Johnston et al., 
2006). A consistent finding in studies is that there 
is a slight excess of males affected with an M:F 
ratio about 1.5:1. More recent data suggests that the 
gender ratio may be approaching equality (Worms, 
2001; Abhinav et al., 2007; Zoccolella et al., 2008; 
Logroscino et al., 2008). Mortality rates of ALS in 
the 1990’s ranged from 1.54 to 2.55 per 100,000/
year and a more recent study estimated the figure to 
be 1.84 per 100,000 persons (Worms, 2001; Sejvar 
et al., 2005). The mean age of onset for SALS var-
ies between 55-65 years with a median age of onset 
of 64 years (Haverkamp et al., 1995). Only 5% 
of cases have an onset before the age of 30 years, 
although juvenile sporadic onset cases are being 
increasingly recognized (Gouveia and de Carvalho, 
2007). Bulbar onset is commoner in women and in 
older age groups, with 43% of patients over the age 
of 70 presenting with bulbar symptoms compared to 
15% below the age of 30 (Beghi et al., 2007; Forbes 
et al., 2004).
Although most cases of ALS are sporadic, about 
7% of cases have a family history of ALS (FALS). 
Often there is a Mendelian inheritance and high 
penetrance, with most cases having autosomal domi-
nant (AD) pattern of inheritance, although autoso-
mal recessive (AR) pedigrees have been reported 
(Mulder et al., 1986; Gros-Louis et al., 2006). The 
age of onset of FALS is about a decade earlier than 
for sporadic cases, affects males and female equally, 
and have a shorter survival (Li et al., 1988; Veltema 
et al., 1990). Age of onset in FALS has a normal 
Gaussian distribution, whereas SALS has an age 
dependant incidence (Strong et al., 1991). Juvenile 
onset ALS (JALS) is a term used when age of onset 
is less than 25 years (Ben Hamida et al., 1990). 
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Most cases are AR although AD inheritance linked 
to chromosome 9q34 (ALS4, senataxin) has been 
reported (Chance et al., 1998). Recessive forms have 
been mapped to chromosome regions 2q33 (ALS2, 
alsin), and 15q12-21 (Hentati et al., 1994; 1998).
Geographic loci of the Western Pacific form of 
ALS, where the prevalence is 50-100 times higher 
than elsewhere world have been reported, although 
the cause of these aggregations remains elusive 
(Steele and McGeer, 2008). These populations 
include the Chamorro people of Guam and Marianas 
island, the Kii peninsula of Honshu Island, and the 
Auyu and Jakai people of south west New Guinea, 
in whom ALS is associated with the Parkinsonism 
and dementia (ALS-PD complex). More recent 
studies however have shown a decrease in incidence 
of both ALS and PDC in these areas over the past 
40 years, although the incidence of PDC slightly 
increased during the eighties and nineties (Steele 
and McGeer. 2008; Plato et al., 2003; Waring et al., 
2004; Kuzuhara and Kokubo, 2005).
Relevant clinical features for early 
diagnosis
Approximately two thirds of patients with typical 
ALS have a spinal form of the disease: they present 
with symptoms related to focal muscle weakness, 
which may start either distally or proximally in the 
upper or lower limbs. Rarely, patients may notice 
muscle wasting before onset of weakness. Patients 
may have noticed fasciculations (involuntary muscle 
twitching) or cramps preceding the onset of weak-
ness or wasting for some months or even years. 
The weakness is of insidious onset, usually asym-
metrical, the controlateral limbs developing weak-
ness and wasting sooner or later. Most patients go 
on to develop bulbar and eventually respiratory 
symptoms. Gradually, spasticity may develop in the 
weakened atrophic limbs, affecting manual dexter-
ity and/or gait. Occasionally encountered symptoms 
include bladder dysfunction (such as urgency of 
micturition), sensory symptoms, and multi-system 
involvement (e.g. dementia, parkinsonism).
Patients with bulbar onset ALS usually present with 
dysarthria. Patients develop dysphagia for solid or 
liquids after noticing speech disturbances. Limbs 
symptoms can develop almost simultaneously with 
bulbar symptoms and in the vast majority of cases 
will occur within 1-2 years. Almost all patients with 
bulbar symptoms develop sialorrhoea with exces-
sive drooling due to difficulty swallowing saliva 
and mild UMN type bilateral facial weakness, which 
affects the lower part of the face. “Pseudobulbar” 
symptoms such as emotional lability and excessive 
yawning are seen in a significant number of cases.
About less than 5% of ALS patients present with 
respiratory weakness without previous limb or bulbar 
signs (de Carvalho et al., 1996; Chen et al., 1996), 
showing symptoms of respiratory failure or noctur-
nal hypoventilation such as dyspnoea, orthopnoea, 
disturbed sleep, morning headaches, excessive day 
time somnolence, anorexia, decreased concentration, 
and irritability or mood changes (Polkey et al., 1999).
Early examination in the course of limb onset 
disease reveals focal muscle atrophy especially 
involving the muscles of the hands forearms, or 
shoulders in the upper limbs, and proximal thigh or 
distal foot muscle in the lower limbs. Fasciculations 
are usually visible in more than one muscle group. 
Spasticity is evident in the upper limbs by increased 
tone and a supinator “catch”, and in the lower limbs 
with a patellar “catch” and clonus together with 
hypertonia. Tendon reflexes are brisk usually in a 
symmetrical manner, including the finger jerks in 
the upper limbs and positive crossed adductor reflex 
in the lower limbs with abnormal spread of tendon 
reflexes beyond the stimulated muscle group. The 
Hoffmann’s sign may be positive in the upper limbs 
and plantar response is often extensor. In patients 
with bulbar dysfunction, dysarthria may arise from 
either LMN pathology or UMN disorder (pseudo-
bulbar palsy), leading to slow slurred speech or a 
nasal quality. The jaw jerk may be brisk, especially 
in bulbar-onset disease. An UMN type facial weak-
ness affects the lower half of the face causing dif-
ficulty with lip seal and blowing cheeks, but often 
varying degrees of UMN and LMN facial weakness 
coexist. The gag reflex is preserved and is often 
brisk while the soft palate may be weak. Patients 
develop fasciculations and wasting of the tongue. 
Tongue movements are slowed also due to spastic-
ity. The rest of the cranial nerves remain intact, 
although in late stages of the disease patients may 
very rarely develop a supranuclear gaze palsy or 
oculomotor palsy (Okuda et al., 1992; Kobayashy 
et al., 1999). Sensory examination is usually unre-
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markable. As disease progresses, patients develop 
the characteristic picture of the combination of 
UMN and LMN signs within the same central ner-
vous system region, affecting the bulbar, cervical, 
thoracic and lumbar territories. Respiratory failure 
and other cardio-pulmonary complications are the 
usual cause of death in ALS.
Clinical features of variant disorders
Variants of ALS have differing clinical presenta-
tions, rate of progression and prognosis. Opinion 
is divided as to whether these syndromes should 
be classed as separate entities from ALS, although 
there is evidence that they may be a common molec-
ular pathology.
PMA accounts for 5-10% of patients with ALS, and 
indicates a pure LMN syndrome without accompa-
nying UMN signs (Norris et al., 1993). It is almost 
always of limb onset, but patients may eventually 
develop swallowing difficulties. It is reported that 
up to 50% of patients may develop UMN signs and 
go on to develop typical ALS picture (Traynor et 
al., 2000b).
The “flail arm” and “flail leg” variants are initially 
localized forms with a predominantly lower motor 
neuron presentation. In the flail arm variant, which 
also is known as the Vulpian-Bernhardt syndrome 
and Brachial amyotrophic diplegia (Katz et al., 
1999), weakness and wasting predominantly affect 
the proximal upper limb in a symmetrical pattern, 
leading to severe wasting around the shoulder girdle 
and the arms hanging flaccidly either side. Typically, 
the tendon reflexes in the upper limbs are depressed 
or absent, but patients may have retained reflexes or 
focal brisk reflexes especially in the unaffected limb 
when the disease is asymmetrical at the onset. The 
lower limbs remain strong for some years but even-
tually spasticity and wasting develops. Swallowing 
difficulties and diaphragmatic weakness are usually 
late features (Hu et al., 1998; Couratier et al., 2000). 
In the flail leg syndrome, weakness and wasting 
begins in the distal lower limbs affecting both lower 
limbs in a symmetrical manner. Again the clinical 
features are of a LMN syndrome with hypotonia 
and depressed tendon reflexes. Pyramidal signs are 
usually absent, although it is not unusual for these 
patients to have focal brisk reflexes in the unaffected 
limb when the disease is asymmetrical. The unusual 
clinical picture together with lack of neurophysi-
ological evidence of denervation in other regions 
can lead to considerable diagnostic delays. These 
two variants characteristically show slower progres-
sion compared to more typical forms of ALS (Hu 
et al., 1998; Guidetti et al., 1996; Katz et al., 1999; 
Talman et al., 2002).
PLS is a clinically progressive pure UMN syndrome 
that cannot be attributed to another disease process. 
There is ongoing debate as to whether this syndrome 
is in fact an entirely separate disorder to ALS, but 
there is evidence from pathological studies that hall-
marks of ALS such as ubiquitinated inclusions are 
present in this condition. Patients present with a pure 
UMN syndrome with either absent or minimal LMN 
signs. It can be difficult to differentiate PLS from 
ALS during the early stages as some patients with 
typical ALS may only manifest UMN signs. For 
this reason, some authors have suggested that LMN 
signs must be absent for 3 years from onset to confi-
dently diagnose PLS (Pringle et al., 1992). However, 
there may be electrophysiological evidence of LMN 
involvement in PLS patients despite the absence of 
clinical LMN signs, and some patients may develop 
wasting of small muscles of the hands, adding to the 
diagnostic confusion (Le Forestier et al., 2001a,b), 
a condition called by some authors as “UMN-
dominant ALS” (Gordon et al., 2006; Tartaglia et 
al., 2007). Prognosis for PLS is considerably better 
than for typical ALS (Gordon et al., 2006).
A new issue in ALS diagnosis:
the cognitive impairment (ALSci)
The more recent heightened interest in ALS cogni-
tive efficiency is partly due to the relevance played 
by patient cognitive integrity in giving an informed 
consent in the advanced stages of the disease when 
patients face important end-life decisions.
Patients who have ALS also diagnosed with a cogni-
tive disorder are characterized as having ALS with 
cognitive impairment, named ALSci. The impair-
ment reflects frontal lobe dysfunction but must not 
be considered synonymous with the more severe 
dementia associated with FTD. Numerous studies 
show that the primary deficits in ALSci occur in the 
domains of attention (Frank et al., 1997), executive 
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functions (Lomen-Hoerth et al., 2003; Phukan et al., 
2007; Stukovnik et al., 2010), cognitive flexibility 
(Frank et al., 1997; Strong et al., 1999), word gen-
eration, and retrieval (Abrahams et al., 2000; 2004).
Many studies have identified impaired intrinsic 
response generation and particularly abnormalities 
in verbal fluency (Ludolph et al., 1992; Massman 
et al., 1996; Abrahams et al., 2000; Lomen-Hoerth 
et al., 2003; Abrahams et al., 2005; Ringholz et al., 
2005; Murphy et al., 2007a,b), as also reviewed by 
Phukan et al., 2007 (see Table I).
Consistent with a frontal syndrome, visuospatial 
functions, praxis, and memory storage are typi-
cally spared (Massman et al., 1996; Abrahams et 
al., 2005; Ringholz et al., 2005), whereas reports 
suggesting that impaired memory may be found 
probably reflect deficiencies in retrieval processes 
associated with frontal lobe dysfunction rather than 
an amnestic process (Mantovan et al., 2003).
Estimates of the prevalence of cognitive impair-
ment in patients who have ALS are various, ranging 
from 10% (Poloni et al., 1986) to 75% (Frank et al., 
1997). This difference is partly due to methodologi-
cal issues and differences in the neuropsychological 
tests used. Moreover, neuropsychological testing is 
not always been adapted to motor or verbal impair-
ments of ALS patients. In fact, where neuropsycho-
logical testing is the gold standard for diagnosis, 
reports have used varied cognitive tests and different 
cut-offs for distinguishing normal from abnormal, 
resulting in different conclusions about the nature 
of the disease. As remarked by Phukan et al. (2007), 
even if untimed neuropsychological tests and control 
for lower motor speed have been suggested, exten-
sive validation of these instruments is still needed.
A single consensus on diagnostic criteria for ALSci 
has not been reached, but an increasingly common 
threshold used in the field requires the presence of 
two or more neuropsychological scores at or below 
the fifth percentile compared with a normative 
group. This requirement assumes the tests are part 
of a comprehensive battery including measures that 
are distinct and sensitive to executive functioning 
and language processing. With this methodology, 
the incidence of ALSci within a typical tertiary ALS 
Center seems to be approximately 50% (Ludolph et 
al., 1992; Ringholz et al., 2005).
Whether a specific clinical presentation predicts 
ALSci is not entirely clear and this may be critical 
in early diagnosis. Several studies have indicated 
an association of ALSci with bulbar involvement 
(Massman et al., 1996; Strong et al., 1999; Lomen-
Hoerth et al., 2003). Studies suggesting a correlation 
between dysarthria and higher levels of distractibil-
ity (Abrahams et al., 1996) or between pseudobulbar 
affection and cognitive impairment reflect similar 
conclusions (McCullagh et al., 1999). Pathologic 
studies have found that patients who have bulbar 
palsy may have a degenerative process that extends 
beyond the motor cortex into frontotemporal lobar 
regions (Neary et al., 2000). The relationship is 
not entirely clear, however, as other studies have 
failed to find correlations between ALSci and bul-
bar involvement (Massman et al., 1996; Frank et 
al., 1997; Portet et al., 2001; Ringholz et al., 2005). 
The recent meta-analysis study of Raaphorst et al. 
(2010) was not able to support the suggested relation 
between bulbar ALS and cognitive deficits.
The same meta-analysis study by Raaphorst et 
al. (2010), aiming to clarify the magnitude and 
pattern of cognitive impairment in non-demented 
ALS patients, analyzed 48 neuropsychological stud-
ies: sixteen studies were eligible for inclusion in 
the meta-analysis that further confirmed that non-






Language (i.e., verbal fluency, naming deficits)
Memory (i.e., working memory)
Visuoperceptual skills
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demented ALS patients may suffer from decreased 
cognitive abilities, further corroborating previous 
observations that motor neuron disease is not solely 
confined to the upper and lower motor neuron tracts 
per se. Apparently, cognitive domains subserved 
by non-motor zones in the cerebral cortex resulted 
affected in ALS patients as well. In decreasing order 
of effect sizes the following domains are impaired 
in ALS patients: Mini Mental State Examination 
(MMSE), psychomotor speed, verbal fluency, lan-
guage, visual memory, immediate verbal memory 
and executive functioning. No impairments were 
found for verbal IQ, delayed verbal memory, atten-
tion, visuoperceptual and visuoconstructive func-
tions. The heterogeneity between studies was fairly 
low, indicating that the observed pooled effects are 
reliable estimates. With the exception of the domains 
of language, psychomotor speed and executive func-
tioning, clear indications for publication bias were 
not demonstrated. The results of the fluency and psy-
chomotor speed domains may have been influenced 
by slight motor impairment (Raaphorst et al., 2010). 
New technologies such as eye-tracking (ET) or Brain 
Computer Interface (BCI) have been recently used to 
test cognition and frontal functions in ALS patients 
(Iversen et al., 2008; Poletti et al., 2009).
The need for a validated neuropsychological battery 
that allows cognitive assessment from the onset to 
the late stages of the disease is a matter of primary 
importance. New technologies will allow neuropsy-
chological testing of patients who are not testable at 
present.
Behavioral changes in ALS (ALSbi)
The term ALSbi describes behavioral impairment 
that does not meet diagnostic criteria for FTD, yet 
reflects a mood-independent change since ALS 
onset. Estimates of the prevalence of ALSbi vary 
depending on methodology and diagnostic criteria. 
One feature consistent across several studies is the 
presence of apathy that can occur despite significant 
cognitive impairments are present (Grossman et 
al., 2007; Murphy et al., 2007a,b) with abnormal 
levels of apathy reported in 55% of ALS patients 
(Grossman et al., 2007). Apathy correlated with 
deficits in verbal fluency but not with depression, 
disease duration, forced vital capacity, or ALS-FRS 
scores. Similar to cognitive impairment in ALS, no 
current evidence shows that ALSbi progresses to 
ALS-FTD or that it is part of a continuum. However, 
disinhibition, which is a common feature in FTD, is 
not seen with high frequency as a behavioural mani-
festation of ALS.
Although apathy could develop on an organic basis, 
it is also known to be a manifestation of fatigue, 
respiratory weakness, impaired sleep, anxiety, or 
medication side effects. Apathy may also reflect a 
psychologic coping mechanism for patients who have 
terminal illness or paralysis. It occurs with a much 
higher frequency in ALS than depression, which 
occurs in 10% (Patten et al., 2007) to 26% (Wicks 
et al., 2007) of patients. Behavioural impairment 
is typically assessed through caregiver interview 
as opposed to direct patient questioning, primar-
ily because patients who have behavioural changes 
may lack insight. Standardized measures for assess-
ment include the Frontal Behavioural Inventory 
(Kertesz et al., 1997), Frontal Systems Behavioural 
Scale (Stout et al., 2003), and the Neuropsychiatric 
Inventory (Cummings et al., 1994). Diagnostic 
criteria that have been proposed for ALSbi include 
frontal lobe type behavioural impairment in two or 
more areas measured using one of these standard-
ized caregiver interviews (Murphy et al., 2007a,b).
frontotemporal dementia in ALS
(ALS-fTD)
The Neary criteria are most commonly used for 
diagnosing FTD (Neary et al., 1998). A diagnos-
tic approach that relies solely on cognitive testing 
may fail to detect patients who have early or mild 
ALS-FTD, in whom these behavioural abnormali-
ties can occur in the context of a relatively intact 
cognition (Neary et al., 2000). Varied frequencies 
of FTD subtypes within the ALS population have 
been reported. These discrepancies likely reflect 
biases introduced by the methodology used for diag-
nosis and subjectivity in behavioural assessment. 
Using a combination of cognitive testing and the 
Neary criteria (Lomen-Hoerth et al., 2003), 65% of 
patients who where diagnosed with ALS-FTD had 
the behavioural (frontal) variant, characterized by 
apathy, disinhibition, and poor social monitoring. In 
contrast, another study (Ringholz et al., 2005) found 
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that 63% of patients who had ALS and dementia 
had a language variant of FTD, more consistent with 
PNFA or semantic dementia.
A population-based study of a sample of patients 
who had ALS estimated that 17% had frank demen-
tia and 11% had clear aphasia (Rakowicz et al., 
1998), whereas in tertiary care clinics, the preva-
lence of impairment meeting criteria for overt 
dementia has ranged from 15% (Ringholz et al., 
2005) to 41% (Lomen-Hoerth et al., 2003). Rippon 
et al. (2006) reported dementia in 23% of their ALS 
cohort but used Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition (DSM-IV) crite-
ria, which uses memory impairment as the defining 
feature of dementia.
A small subset of patients, perhaps as low as 5%, 
presents with clear FTD. These patients differ dra-
matically from those who have ALSci because of 
vast behavioural alterations, which usually begin 
before motor weakness becomes apparent. Many of 
these patients present initially to centers that focus 
on cognition, and they may be underrepresented in a 
center focusing on ALS.
In contrast to ALSci, FTD symptoms typically occur 
before ALS symptoms. In a study of 24 patients 
who had motor neuron disease-FTD (MND-FTD) 
(Guedj et al., 2007), 58% experienced the onset of 
FTD more than 3 years before MND, whereas 38% 
reported simultaneous onset. A prospective study 
of patients who had ALS found that those who met 
criteria for a dementia exhibited cognitive or behav-
ioural decline an average of 7 years and 7 months 
before motor symptoms (Murphy et al., 2007a,b).
The incidence of clinical or EMG abnormalities 
suggestive of MND within an FTD clinic is approxi-
mately 15% (Lomen-Hoerth et al., 2003) but no 
clear reports exist of patients in ALS centers devel-
oping frank FTD during the course of motor degen-
eration. Some experts hypothesize that patients 
who have ALS die before cognitive or behavioural 
impairments become apparent, in contrast to patients 
who develop FTD and have years to develop ALS. 
The loss of speech and movement in ALS may also 
mask the cognitive and behavioural degradation if 
they occur. An alternative explanation would be that 
patients who have typical ALS rarely develop FTD.
Reports have suggested that FTD reflects one end 
of a disease continuum, with ALSci as the more 
benign, initial manifestation. The argument is dif-
ficult to support when considering temporal data. 
Prospective studies have failed to detect significant 
progression of ALSci over time (Moretti et al., 2002; 
Kilani et al., 2004; Abrahams et al., 2005; Screiber et 
al., 2005). Robinson et al. (2006) reported declines 
in cognitive test scores, defined by a 1 standard 
deviation change, but they did not specify whether 
performances declined to levels consistent with 
clinical impairment (i.e., below the fifth percentile). 
Strong et al. (1999) documented cognitive changes 
over 6 months in a small cohort of patients who had 
bulbar-onset but experienced no progression to typi-
cal FTD. In contrast, patients who present to ALS 
clinics with frank FTD show clear progression of 
dementia along with motor decline. Moretti et al. 
(2002) found that among a cohort of patients docu-
mented at baseline to have varying degrees of cog-
nitive and behavioural impairment, progression was 
only evident in those initially diagnosed with FTD.
Diagnostic methods
The expert clinician after a careful neurological 
examination, in presence of UMN and LMN signs 
in the same anatomical segment with asymmetrical 
localization is able to suspect the diagnosis of ALS 
but he needs a neurophysiological confirmation per-
formed by an expert colleague. The clinician and the 
neurophysiologist represent a monad and they have 
to relay on each other: they have the responsibility 
for the diagnosis of this deadly disease. According 
to different surveys, the time required to confirm 
the diagnosis of ALS from first signs/symptoms is 
approximately 1 year in Italy as in Europe (Chiò and 
Silani, 2001; Borasio et al., 2001).
Electrophysiological studies
Electrophysiological studies primarily have to docu-
ment LMN dysfunction in clinically involved and 
uninvolved regions, and secondarily to exclude 
other disease processes. The first published crite-
ria for electrodiagnosis of ALS were by Lambert 
in 1957 and 1969. The revised El-Escorial criteria 
(Brooks et al., 2000) have proposed electrophysi-
ological criteria for the diagnosis of ALS, which 
have been further refined in December 2006 at a 
consensus conference on Awaji Island, Japan (de 
Carvalho et al., 2008). It is important to bear in mind 
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that clinical neurophysiological examination is used 
in the diagnosis of ALS when the diagnosis is clini-
cally suspected, and suggestive neurophysiological 
abnormalities alone cannot clinch the diagnosis 
without the clinical support.
Nerve conduction studies
(motor and sensory)
Nerve conduction studies are required for the diag-
nosis principally to define and exclude other disor-
ders of peripheral nerve, neuromuscular junction, 
and muscle that may mimic or confound the diag-
nosis of ALS. These studies should generally be 
normal or near normal, unless the compound muscle 
potential is small (Brooks et al., 2000). In ALS, the 
distal motor latency (DML) and motor conduction 
velocity (MCV) remain almost normal, never fall-
ing below 70% of the upper or lower limit of normal 
(Cornblath et al., 1992; Mills et al., 1998; de Carvalho 
and Swash, 2000). Motor studies are also important 
in excluding multifocal motor neuropathy, by the 
detection of partial conduction block. A marked 
reduction of proximal amplitude or negative-peak 
area as compared with the distal ones (over 50%), in 
short segments (excluding entrapment sites), implies 
partial conduction block (de Carvalho et al., 2001). 
F-wave studies are particularly useful in assessing 
proximal conduction and abnormalities have been 
reported in ALS. These include increased F-wave 
latency with normal frequency and increased ampli-
tude, and slowing of F-wave velocity with decreased 
F-wave frequency. Prominent UMN features may be 
associated with an increased F-wave frequency (de 
Carvalho and Swash, 2000).
The sensory nerve conduction studies can be abnor-
mal in the presence of entrapment syndromes and 
coexisting peripheral nerve disease (Brooks et al., 
2000). There is also recent evidence of sub-clinical 
involvement of the sensory system in 10-20% of 
patients with ALS, suggesting an additional poly-
neuropathy or sensory ganglionopathy (Isaacs et al., 
2007; Pugdahl et al., 2007).
Conventional electromyography
Concentric needle electromyography (EMG) pro-
vides evidence of LMN dysfunction which is 
required to support the diagnosis of ALS, and should 
be found in at least two of the four CNS regions: 
brainstem (bulbar/cranial motor neurons), cervical, 
thoracic, or lumbosacral spinal cord (anterior horn 
motor neurons). For the brainstem region it is suf-
ficient to demonstrate EMG changes in one muscle 
(e.g. tongue, facial muscles, jaw muscles). For the 
thoracic spinal cord region it is sufficient to demon-
strate EMG changes either in the paraspinal muscles 
at or below the T6 level or in the abdominal muscles. 
For the cervical and lumbosacral spinal cord regions 
at least two muscles innervated by different roots 
and peripheral nerves must show EMG changes 
(Brooks et al., 2000).
The revised El-Escorial criteria require that both evi-
dence of active or ongoing denervation and chronic 
partial denervation is required for the diagnosis 
of ALS, although relative proportions vary from 
muscle to muscle (Brooks et al., 2000).
Signs of active denervation consist of:
1. fibrillation potentials;
2. positive sharp waves.
Signs of chronic denervation consist of:
1. large motor unit potentials of increased dura-
tion with an increased proportion of polyphasic 
potentials, often of increased amplitude;
2. reduced interference pattern with firing rates 
higher than 10 Hz (unless there is a significant 
UMN component, in which case the firing rate 
may be lower than 10 Hz);
3. unstable motor unit potentials.
Fasciculation potentials are an important character-
istic finding in ALS, although they can be seen in 
normal muscles (benign fasciculations) and are not 
present in all muscles in ALS patients. In benign 
fasciculations the morphology of the fascicula-
tion potentials are normal, whereas in fasciculation 
potentials associated with neurogenic change there 
are abnormal and complex morphology (Janko et 
al., 1989; de Carvalho et al., 2008). The Awaji 
group suggest that the presence of abnormal com-
plex fasciculation potentials in a muscle showing 
neurogenic change can be considered equivalent in 
importance to fibrillation potentials or positive sharp 
waves (de Carvalho et al., 2008).
Transcranial magnetic stimulation
and Central motor conduction studies
Transcranial magnetic stimulation (TMS) allows a 
noninvasive evaluation of the corticospinal motor 
pathways, and allows detection of UMN lesions in 
patients who lack UMN signs. Motor amplitude, 
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cortical threshold, central motor conduction time 
and silent periods can be easily evaluated using this 
method (Eisen and Shtybel, 1990). Central motor 
conduction time (CMCT) is often marginally pro-
longed to muscles of at least one extremity in ALS 
patients. Electrophysiological features compatible 
with UMN involvement include (Brooks et al., 
2000):
1. up to a 30% increase in central motor conduction 
time determined by cortical magnetic stimula-
tion;
2. low firing rates of motor unit potentials on maxi-
mal effort.
Marked prolongation in the CMCT is seen in FALS 
patients with D90A SOD1 mutations and patients 
with the flail arm and flail leg variants (Osei-Lah 
et al., 2004; Vucic and Kiernan, 2007; Cappellari et 
al., 2008).
Quantitative electromyography
Motor unit number estimation (MUNE) is a special 
electrophysiological technique that can provide a 
quantitative estimate of the number of axons inner-
vating a muscle or group of muscles. MUNE con-
sists of a number of different methods (incremental, 
multiple point stimulation, spike-triggered averag-
ing, F-wave, and statistical methods), with each 
having specific advantages and limitations. Despite 
the lack of a perfect single method for performing 
MUNE, it may have value in the assessment of pro-
gressive motor axon loss in ALS, and may have use 
as an end-point measure in clinical trials (Bromberg 
et al., 2008).
Neuroimaging studies
The most important use of neuroimaging is in 
the diagnosis of ALS to exclude treatable struc-
tural lesion that mimics ALS by producing varying 
degrees of UMN and LMN signs, especially in those 
with clinically probable or possible ALS. The WFN 
revised criteria state that imaging studies are not 
required in cases that have clinically definite disease 
with bulbar or pseudobulbar onset as it is unlikely 
that structural lesions can mimic clinically definite 
disease (Brooks et al., 2000). Magnetic resonance 
imaging (MRI) can be used in revealing lesions in 
the corticospinal tracts in ALS. The most character-
istic finding in ALS is hyperintensity of the cortico-
spinal tracts on T2-weighted, proton density weight-
ed and FLAIR-weighted MRI, and is best visualised 
in the brain and brainstem and at a less extent in the 
spinal cord (Goodin et al., 1988; Thorpe et al., 1996; 
Abe et al., 1997; Waragai, 1997). T2 weighted MRI 
may also show hypointensity of the primary motor 
cortex, usually along the posterior bank of the pre-
central gyrus, although this is an inconsistent and 
non-specific finding (Oba et al., 1993).
More advanced neuroimaging modalities such as 
magnetic resonance spectroscopy, diffusion weight-
ed imaging (DWI), diffusion tensor imaging (DTI), 
magnetic resonance voxel-based morphometry and 
functional imaging techniques (fMRI, PET and 
SPECT) have a limited role in routine clinical 
practice but have shown promise in understanding 
pathophysiology of the disease in vivo, identification 
of potential biomarkers of disease progression and 
identifying disease changes earlier in the course of 
the disease facilitating earlier diagnosis (Ellis et al., 
1998; 1999; Turner et al., 2000; Kalra and Arnold, 
2003; Turner et al., 2004; 2009).
Neuroimaging in amyotrophic lateral
sclerosis with cognitive impairment
Several imaging studies have described abnormali-
ties outside the motor cortex in patients who have 
ALS compared with normal controls, and differenc-
es between patients who have ALS and neuropsy-
chological abnormalities and those who are cogni-
tively normal (Hatazawa et al., 1988; Ohnishi et al., 
1990; Ludolph et al., 1992; Abrahams et al., 1996; 
2000; Lloyd et al., 2000; Neary et al., 2000; Guedj 
et al., 2007; Murphy et al., 2007a,b). ALS patients 
have significantly lower frontal and overall cortical 
metabolism (Dalakas et al., 1987; Hatazawa et al., 
1988; Ohnishi et al., 1990; Ludolph et al., 1992), 
whereas regional cerebral blood flow to nonmotor 
areas is reduced in patients who have ALS regard-
less of whether they have cognitive impairment 
(Kew et al., 1993; Lloyd et al., 2000). Larger ventri-
cles have been reported compared with age-matched 
controls (Frank et al., 1997) with changes in frontal 
lobe white matter (Kew et al., 1993; Abrahams et al., 
2005) and prefrontal and temporal gray matter, sug-
gesting atrophy (Chang et al., 2005). Frontotemporal 
white matter changes have been described in cogni-
tively normal patients who have ALS, although the 
changes were greater when cognitive impairment 
was present (Abrahams et al., 2005). These findings 
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have been used to support the notion of a continuum 
between ALS and FTD (Abe et al., 1997).
A specific cause of ALSci can be gathered from vari-
ous imaging studies that have attempted to localize 
abnormalities in verbal fluency, because this find-
ing tends to correlate the highest with this cognitive 
syndrome. These studies have resulted in various 
findings. One study using positron emission tomog-
raphy (PET) found that activity in the dorsolateral 
prefrontal cortex is decreased in patients who have 
ALS with cognitive impairment compared with those 
who are unimpaired and controls (Abrahams et al., 
1996). Significantly reduced activation of the middle 
and inferior frontal gyri, anterior cingulate cortex, 
and parietal and temporal lobes was found in nonde-
mented patients with ALS relative to controls during 
a letter fluency fMRI task. A confrontation naming 
fMRI task also revealed an impaired activation of a 
prefrontal region (including Broca area) and areas of 
the temporal, parietal, and occipital lobes. This pat-
tern of dysfunction correlated with cognitive deficits 
on both word fluency and confrontation naming 
(Abrahams et al., 2004). Functional cortical changes 
have been observed in patients with ALS without 
cognitive/behavioral impairment during processing 
of socioemotional stimuli (i.e. pictures of persons 
in emotional situations). Compared with controls, 
patients with ALS showed an increased activation 
of the right supra-marginal gyrus (Lule et al., 2007).
A subset of patients who had bulbar-onset who 
were shown to have progressive neuropsychological 
deficits over a 6-month interval were found to have 
structural changes localized to the anterior cingulate 
gyrus.
The imaging correlates of patients who have definite 
ALS-FTD, however, seem to be more consistent 
with those of FTD in general. Voxel-based mor-
phometry showed that frontal volume loss patterns 
were similar between ALS and ALS-frontotemporal 
lobar degeneration (FTLD) cohorts (Chang et al., 
2005). However, volume reductions in patients who 
had ALS-FTLD were greater, particularly in the left 
hemisphere, than in patients who had ALS and no 
dementia.
Another study found right temporal lobe volume 
loss was most predictive of classification in a fronto-
temporal dysfunction group (Murphy et al., 2007). A 
single photon emission CT study (Guedj et al., 2007) 
compared patients who had FTD and MND-FTD to 
age- and gender-matched controls. Clinically, all 
patients had frontal variant FTD, and patients who 
had FTD and MND-FTD had the same pattern of 
asymmetric anterior hypoperfusion involving fron-
tal, temporal, cingular, and insular cortices. Bilateral 
hypoperfusion of the thalamus and striatum was also 
noted.
A recent review further summarizes the most recent 
neuroimaging findings in ALS (Agosta et al., 2010).
Neuropsychological testing
A number of screening batteries have been proposed 
for diagnosing cognitive impairment (Flaherty-
Craig et al., 2006; Gordon et al., 2007; Phukan et 
al., 2007). Verbal fluency deficits are a sensitive 
measure of cognitive dysfunction if testing is appro-
priately modified to account for physical deficits and 
results standardized to educational attainment and 
pre-morbid IQ (Phukan et al, 2007). More exten-
sive full neuropsychological assessment is war-
ranted if cognitive impairment has been suspected. 
Considering progression of cognitive impairment in 
the disease, a careful prospective population-based 
cohort study is required to determine prevalence 
and incidence of cognitive impairment in ALSci, 
ALSbi, the rate of progression and the degree of 
clinical overlap between the subgroups. The neu-
rologist making diagnosis of ALS needs to realize 
that a frontotemporal syndrome occurs in up to 
50% of ALS, is associated with a poorer prognosis 
and symptoms of cognitive dysfunction may appear 
before or after the onset of motor symptoms. The 
MMSE per se is an insensitive test for ALSci and 
ALSbi and rapid screening tools that include tests of 
verbal fluency can identify patients in whom more 
detailed neuropsychological evaluation is mandated. 
In all patients with frontal dysexecutive syndromes 
care needs to be taken to ensure informed consent 
during decision-making; capacity issues may need 
to be considered.
Muscle biopsy and neuropathological
studies
Biopsy of skeletal muscle or other tissues is not 
required for diagnosis, unless to rule out a mimic 
syndrome (e.g. Inclusion body myositis). In addi-
tion, muscle biopsy may be used to demonstrate 
LMN dysfunction in a body region when clinical or 
electrophysiological findings do not support this evi-
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dence. Histological findings that are compatible with 
the diagnosis of ALS include (Brooks et al., 2000):
– scattered hypertrophied muscle fibres;
– no more than a moderate number of target or 
targetoid fibres;
– fibre type grouping of no more than mild-to-
moderate extent;
– the presence of a small number of necrotic mus-
cle fibres.
Other laboratory studies
There are a few other investigations that may 
be considered mandatory in the work-up of an 
ALS patient. Clinical laboratory tests that may be 
abnormal in otherwise typical case of ALS include 
(Brooks et al., 2000):
– muscle enzymes (serum creatine kinase [unusual 
above ten times upper limit of normal], ALT, 
AST, LDH);
– serum creatinine (related to loss of skeletal mus-
cle mass);
– hypochloremia, increased bicarbonate (related to 
advanced respiratory compromise);
– elevated CSF protein (uncommonly more than 
100 mg/dl).
Genetic factors
20% of cases with autosomal dominant FALS and 
2% of patients with SALS show mutations in the 
Copper-Zinc superoxide dismutase (SOD1) gene 
(Rosen et al., 1993). Mutations in this gene are 
though to cause disease through a toxic gain of 
function rather than causing impairment of the anti-
oxidant function of the SOD1 enzyme (Shaw, 2005). 
Other genes causing familial MND include alsin 
(ALS2) (Hadano et al., 2001; Yang et al., 2001), 
senataxin (ALS4) (Chen et al., 2004), vesicle associ-
ated membrane protein (VAPB, ALS8) (Nishimura 
et al., 2004), angiogenin (Greenway et al., 2004; 
2006) and a mutation in the p150 subunit of dyn-
actin (DCTN1) (Puls et al., 2003; Munch et al., 
2004). More recently, mutations in TARDBP gene 
(encoding the TAR-DNA binding protein TDP-
43) located on chromosome 1p36.22 have been 
linked to familial and sporadic ALS (Kabashi et al., 
2008; Sreedhran et al., 2008; Yokosei et al., 2008). 
Several other gene mutations have been identified 
in sporadic cases which may increase susceptibility 
to ALS, such as mutations in the KSP repeat region 
in the NEFH gene (encoding neurofilament heavy 
subunit) apolipoprotein E e4 genotype (APOE), 
decreased expression of excitatory amino acid trans-
porter 2 (EAAT2) protein and alterations in the 
vascular endothelial growth factor (VEGF) gene to 
name a few. In 2009 FUS/TLS has been reported 
(Vance et al., 2009; Kwiatkowski et al., 2009) and 
Italian affected families described (Ticozzi et al., 
2009). More recently spatacsin has been reported in 
autosomal recessive juvenile ALS (Orlacchio et al., 
2010), D-amino acid oxidase (DAO), and optineurin 
in isolated cases of FALS (Mitchell et al., 2010; 
Muruyamate al., 2010). More recently, FALS cases 
have been reported with mutations in paraoxonase 
(Ticozzi et al., 2010) (Table II).
The discovery of new genes in FALS and the 
report of mutations in SALS provide phenotype-
genotype correlations that appear so critical for 
early diagnosis of ALS and definition of disease 
duration. Patients with SOD1 mutations usually first 
develop lower limb weakness whereas patients with 
TARDBP mutations had onset predominantly in the 
upper limbs. Patients harbouring FUS mutations 
had various onset sites in the arms, legs or bulbar 
muscles (Millecamps et al., 2010). Evolution of 
ALS can be predicted according to the different gene 
mutations: FUS mutations seem to top lead to the 
most aggressive disease and lifespan is shortened for 
FUS patients. Considerable interfamilial phenotypic 
differences were observed in some families carrying 
various mutations in the SOD1, TARDBP, and FUS 
genes. Age and site of onset vary between members 
of a family further supporting the hypothesis that a 
mutation is not the only factor that determines the 
clinical course of the disease. With regard to the 
clinical characteristics of the FUS-mutated patients, 
the mean age at onset (47.9 years) in our patients 
was similar to that of previously reported FUS-
mutated patients, ranging from 38.2 to 46.3 years 
(Corrado et al., 2010). This suggests that mutations 
in FUS are associated with disease of early onset 
compared with the general mean age of 60 years 
reported for ALS. Interestingly, the two patients 
(one SALS and one FALS) carrying the most com-
mon FUS mutation (p.R521C) exhibited a similar 
unusual presentation, with proximal, mostly sym-
metrical, upper limb onset with axial involvement 
distinct from the typical clinical presentation of 
ALS. Neck flexor/extensor muscle weakness seems 
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to be a further unusual clinical characteristic at dis-
ease onset in the p.R521C-mutated SALS and FALS 
patients, usually being present in only about 0.7% 
of ALS patients (Gourie-Devi et al., 2003). The 
two previously reported FALS cases with p.R521C 
mutations (Ticozzi et al., 2009) presented similar 
clinical characteristics, with symmetrical, proximal 
and axial weakness at onset, further supporting 
the distinct FUS p.R521C clinical phenotype also 
characterized by prevalence of lower motor neuron 
signs. The accurate collection of clinical records 
reporting proximal, axial and neck muscle involve-
ment at the disease onset is an excellent example 
of a genotype-phenotype correlation that, if early 
detected, can address the prompt diagnosis of ALS. 
For a further review of genetics see Ticozzi et al. 
(2011) in this journal.
Differential diagnosis
ALS must be differentiated from the “ALS mimic 
syndromes” which are unrelated disorders that may 
have a similar presentation and clinical features to 
ALS or it’s variants (Rowland and Shneider, 2001). 
See Table III.
Prognosis
Analysis of large patient samples drawn from clinic 
based populations or population registries consis-
tently show that the overall median survival from 
onset of symptoms for ALS ranges between 2-3 
years for bulbar onset cases and 3-5 years for limb 
onset ALS cases. Large clinic cohort studies have 
shown 3 year and 5 year survival rates to be around 
48% and 24% respectively, with approximately 4% 
surviving longer than 10 years, whereas 5 year sur-
vival reported in population based studies is much 
lower and ranges from 4-30% (Chancellor et al., 
1993).
Important prognostic indicators of survival consis-
tently arising from population based studies and 
clinic cohort studies include clinical phenotype 
(PMA and Flail arm have better prognosis than 
Table II. - Genes implicated in Familial Amyotrophic Lateral Sclerosis.
Type Onset Pattern Linkage Gene Protein
ALS1 Adult AD/AR* 21q22.1 SOD1 Cu/Zn superossido dismutase
ALS2 Juvenile AR 2q33-35 ALS2 Alsin
ALS3 Adult AD 18q21
ALS4 Juvenile AD 9q34 SETX Senataxne
ALS5 Juvenile AD 15q15-21 SPG11 Spatacsin
ALS6 Adult AD** 16p11.2-q21 FUS/TLS Fused in sarcoma
ALS7 Adult AD 20p13
ALS8 Adult AD 20q13.33 VAPB VAMP-associatated protein B
ALS9 Adult AD 14q11 ANG Angiogenin
ALS10 Adult AD 1q36 TARDBP TAR DNA-binding protein
ALS11 Adult AD 6q21 FIG4 PI(3,5)P(2)5-fosfatase
ALS12 Adult AD/AR 10p15-p14 OPTN Optineurin
ALS-FTD1 Adult AD 9q21-22
ALS-FTD2 Juvenile AD 9p13.2-21.3
ALS Adult AD/AR 7q21.3-q22.1 PON1-2-3 Paroxonase
ALS Adult AD 2p13 DCTN1 Dinactin
ALS Adult AD 9p13-p12 VCP Valosin-containing protein
AD = autosomic-dominant; AR = autosomic-recessive. * Mutation p.D90A is transmitted AR in the main number of families. ** H517Q mutation 
is trasmitted AR
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Table III - Diseases that can masquerade as Amyotrophic Lateral Sclerosis (in italic the most critical differential diagnosis)
Anatomical abnormalities/compression syndromes:
Arnold-Chiari-1 and other hindbrain malformations
Cervical, foraman magnum or posterior fossa region tumors




Spondylotic myelopathy and/or motor radiculopathy
Syringomyelia
Acquired enzyme defects:
Adult GM2 gangliosidosis (hexosaminidase-A or B deficiency)
Polyglucosan body disease
Autoimmune syndromes:
Monoclonal gammopathy with motor neuropathy
Multifocal motor neuropathy with/without conduction block (MMN)
Dysimmune LMN syndromes (with GM1, GD1b and asialo-GM1 antibodies)
Other dys-immune LMN syndromes including CIDP
Multiple sclerosis








Hyperparathyroidism (secondary due to vitamin D deficiency)
Hypokalemia (Conn’s syndrome)
Exogenous toxins:
Lead (?), mercury (?), cadmium, aluminium, arsenic, thallium, manganese, organic pesticides, neurolathyrism, konzo
Infections:
Acute poliomyelitis
Post-poliomyelitis progressive muscular atrophy syndrome
HIV-1 (with vacuolar myelopathy)
HTLV-1 associated myelopathy (HAM, tropical spastic paraplegia)
Neuroborreliosis
Syphilitic hypertrophic pachymeningitis

















Lymphoproliferative disorders with paraproteinemia and/or oligoclonal bands in the CSF
Pancoast tumor syndrome











Western Pacific atypical forms of MND/ALS (Guam, New Guinea, Kii Peninsula Japan)
Carribean atypical forms of MND-dementia-psp (Guadeloupe)
Madras-form of juvenile onset MND/ALS (South India)
Frontotemporal dementia with MND/ALS (FTD, including Pick’s Disease with amyotrophy)
Multiple system atrophy (MSA)
Olivo-ponto cerebellar atrophy (OPCA/SCA) syndromes
Primary lateral sclerosis (PLS; some subtypes not related to ALS)
Progressive encephalomyelitis with rigidity (PER)
Progressive supranuclear palsy (PSP)
Hereditary spastic paraplegia (HSP; many variants, some subtypes with distal amyotrophy)
Progressive spinal muscular atrophy (PMA; some subtypes not related to ALS)
Spinobulbar muscular atrophy with/without dynactin or androgen receptormutation (SBMA)
SMA I-IV
Brown-Vialetto-van Laere syndrome (early onset bulbar and spinal ALS with sensorineural deafness)
Fazio-Londe syndrome (infantile PBP)
Harper-Young syndrome (laryngeal and distal SMA)
Monomelic sporadic spinal muscular atrophy (BFA, including Hirayama Syndrome)
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typical forms), site of onset (bulbar vs. limb onset), 
age of symptom onset, shorter time from symptom 
onset to diagnosis, baseline FVC decline, El Escorial 
category at presentation, and riluzole use (Traynor 
et al., 2003).
Conclusions
Diagnosis of ALS still remains a clinical diagnosis 
supported by neurophysiological evidence: the con-
tribution of genetic markers is critical but mostly 
applicable to FALS cases. Expert neurologists in 
ALS Referral Center need to be updated on recent 
discoveries and be ready to test patients with distinc-
tive phenotype for selective gene mutations. Some 
general concept are critical to keep in mind: suspect-
ed ALS with symmetrical clinical expression, affect-
ing a young subject with unusual progression have 
to address the neurologist to consider genetic-related 
ALS with familial impact. With the advent of high-
throughput methods – including genome-wide asso-
ciation (GWA) studies, chromatin immunoprecipita-
tion followed by sequencing (ChIP-seq) and RNA 
sequencing (RNA-seq) – acquisition of genome-
scale data has never been easier. Epigenomics, tran-
scriptomics, proteomics and genomics each provide 
an insightful, and yet one-dimensional, view of 
genome function; integrative analysis promises a 
unified, global view. However, the large amount of 
information and diverse technology platforms pose 
multiple challenges for data access and processing 
and, more importantly, need to be moved from the 
laboratory to clinical settings. The neurologist expert 
in ALS in the near future must be able to recognize 
specific genotype-phenotype correlation in ALS 
patients, after carefully evaluating the most specific 
clinical findings: genome analysis will provide the 
molecular diagnosis, ensuring the early diagnosis. 
This will be the clue in the future for timely diag-
nosis of ALS: after many years dominated by the 
clinical method, diagnosis will be for the first time 
supported by molecular evidence derived from high-
throughput methods.
Summary
The diagnosis of Amyotrophic Lateral Sclerosis 
(ALS) is still challenging since there is no a single 
diagnostic test for the disease with the exception of 
mutations of identified genes in a limited number 
of familial ALS patients. The general neurologist 
and the specialist in neuromuscular diseases both 
claim difficulties with early diagnosis of ALS. The 
revised El Escorial Criteria edited in 2000 state that 
to establish the diagnosis of ALS a combination of 
lower and upper motoneuron signs with evidence of 
spread is required. Although primarily intended as 
an algorithm for entering patients into clinical and 
therapeutical studies, the El Escorial Criteria have 
been extensively applied. There was, however, a 
consensus among researchers, since certain clinical 
pictures and, above all, certain neurophysiological 
findings in some special situations were impossible 
to completion of diagnosis. The Awaji new criteria 
in 2006 readdressed the issue of early diagnosis 
that requires more refined neurophysiological sup-
port. The differential diagnosis of ALS is exten-
sive: the cognitive impairment, once considered 
rare, occurs in a large percentage of ALS patients 
and neuropsychological testing needs now to be 
completed for more accurate diagnosis. Genetics 
assumes a significant impact on ALS diagnosis: 
several genes have been recently identified, being 
involved both in familial but also in sporadic cases. 
Specific genotype-phenotype correlations need to 
be recognised for early diagnosis with impact on 
disease duration. In practice, the diagnosis of any 
is made by a process of clinical logic that is defined 
both by the characteristics of the disease itself and 
by an intuitive process of decision making in which 
the clinician weights the clinical evidence accord-
ing to an experiential model built from clinical 
Polyneuropathies with dominating motor symptoms (like HMSN type 2, HMN type 5)
Familial amyloid polyneuropathy (FAP)
Benign fasciculations
Myokymia
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experience gained over time. In ALS this concept 
must be revisited because the recent impact of 
new genetic discoveries requires to the clinician 
a constant update to recognize specific genotype-
phenotype correlations that unquestionably can 
accelerate early diagnosis of ALS, supported by 
genetic testing.
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